A Primer on ADCs: Current and Future Utility in HR+/HER2- mBC
Released On
May 19, 2025
Expires On
May 20, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology, Oncology
Topic(s)
Oncology, Breast Cancer, HR+/HER2-
CME INFO
A PRIMER ON ADCS: CURRENT AND FUTURE UTILITY IN HR+/HER2- MBC
This activity is jointly provided by Global Education Group and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC), in collaboration with Living Beyond Breast Cancer (LBBC).
Acknowledgement
This program is supported by an independent educational grant from Gilead Sciences, INC.
Date of Release/Expiration
This activity was released on May 19, 2025, and is valid until May 20, 2026. Requests for credit must be made no later than May 20, 2026.
Credit Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
Target Audience
The educational design of this activity addresses the needs of breast and medical oncologists and nurse practitioners and physician assistants who treat people with HR+/HER2- breast cancer.
Program Overview
Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic approach for patients with HR+/HER2- breast cancer. ADCs present a unique potential to address the treatment gaps in HR+/HER2- metastatic breast cancer, providing options tailored to patient-specific tumor biology and treatment history. With these advancements in ADC therapies, clinicians must stay updated on the latest clinical data, treatment guidelines, and best practices for managing adverse events. Join an expert panel featuring oncologists Aditya Bardia, MD and Komal Jhaveri, MD to discuss the nuances of treatment sequencing, patient selection, and toxicity management to optimize patient outcomes and patient-centered care. Two patient vignettes will also be shown to highlight the patient voice and journey.
Educational Objectives
After completing this activity, the participant should be better able to:
- Assess the clinical efficacy and safety of current and emerging ADC therapies for HR+/HER2- metastatic breast cancer
- Apply evidence-based strategies for sequencing ADCs in special sub-populations of HR+/HER2-negative metastatic breast cancer patients to optimize therapeutic outcomes
- Review patient-centered approaches in managing adverse events associated with ADCs, including monitoring, early intervention, and multidisciplinary support, to improve patient adherence and outcomes
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Continuing Education
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
his activity should take approximately 60 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC) have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC) do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Technical Support
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected].
Medlive Privacy Policy
Please read the full privacy policy located at: www.medlive.com/privacy-policy